Located in China Medical City (CMC) in Taizhou, Jiangsu province, the plant represents AstraZeneca’s largest investment in a single manufacturing facility globally. It will produce intravenous and oral solid medicines from the end of 2013.
AstraZeneca China president Mark Mallon said the firm had been putting down ‘deep roots in China for many years’ and the new manufacturing facility will provide Chinese patients in urban and rural communities with high quality medicines that are locally produced.
AstraZeneca has had a presence in China since 1993 and in 2010 had a turnover of more than US$1bn in the region.
The firm already operates a state-of-the-art manufacturing and supply site in Wuxi New District, Jiangsu Province.
It has also opened the AstraZeneca Innovation Centre China (ICC) that carries out biomarker research into cancer therapies specifically relevant for Chinese and Asian patients.
AstraZeneca’s key products in the region are Losec, Betaloc, Plendil, Nexium, Crestor, Symbicort and Iressa. Its Chinese operations currently employ around 5,000 people.
The Chinese pharmaceutical market grew from US$10bn in 2004 to US$41bn in 2010 and, according to IMS, is expected to grow to more than $100bn over the next four years.
AstraZeneca China president Mark Mallon said the firm had been putting down ‘deep roots in China for many years’ and the new manufacturing facility will provide Chinese patients in urban and rural communities with high quality medicines that are locally produced.
AstraZeneca has had a presence in China since 1993 and in 2010 had a turnover of more than US$1bn in the region.
The firm already operates a state-of-the-art manufacturing and supply site in Wuxi New District, Jiangsu Province.
It has also opened the AstraZeneca Innovation Centre China (ICC) that carries out biomarker research into cancer therapies specifically relevant for Chinese and Asian patients.
AstraZeneca’s key products in the region are Losec, Betaloc, Plendil, Nexium, Crestor, Symbicort and Iressa. Its Chinese operations currently employ around 5,000 people.
The Chinese pharmaceutical market grew from US$10bn in 2004 to US$41bn in 2010 and, according to IMS, is expected to grow to more than $100bn over the next four years.
No comments:
Post a Comment